information gathered by the Department of Health and Human Services and the Department of Justice with regard to safety, efficacy, and abuse potential of drugs or other substances, and recommends actions to be taken by the Department of Health and Human Services with regard to the marketing, investigation, and control of such drugs or other substances.

The Committee shall consist of a core of 11 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of risk communication, risk management, drug safety, medical, behavioral, and biological sciences as they apply to risk management, and drug abuse. Members will be invited to serve for overlapping terms of up to 4 years. Almost all non-Federal members of this committee serve as Special Government Employees. The core of voting members may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests and is recommended by either a consortium of consumeroriented organizations or other interested persons. In addition to the voting members, the Committee may include one non-voting member who is identified with industry interests.

Further information regarding the most recent charter and other information can be found at https:// www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ DrugSafetyandRiskManagement AdvisoryCommittee/default.htm or by contacting the Designated Federal Officer (see FOR FURTHER INFORMATION CONTACT). In light of the fact that no change has been made to the committee name or description of duties, no amendment will be made to 21 CFR 14.100.

This document is issued under the Federal Advisory Committee Act (5 U.S.C. app.). For general information related to FDA advisory committees, please check https://www.fda.gov/ AdvisoryCommittees/default.htm.

Dated: June 5, 2018.

Leslie Kux,

Associate Commissioner for Policy. [FR Doc. 2018–12442 Filed 6–8–18; 8:45 am] BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Council on Graduate Medical Education

AGENCY: Health Resources and Service Administration (HRSA), Department of Health and Human Services (HHS). **ACTION:** Notice of Advisory Council meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, this notice announces a public meeting of the Council on Graduate Medical Education (COGME). This notice is being published less than 15 days prior to the meeting date due to unforeseen administrative delays.

DATES: Wednesday, June 20, 2018, from 8:30 a.m. to 5:00 p.m. ET, and Thursday, June 21, 2018, from 8:30 a.m. to 2:00 p.m. ET.

ADDRESSES: This meeting is an in person meeting and will offer virtual access through teleconference and webinar. The address for the meeting is 5600 Fishers Lane, Rockville, Maryland 20857.

• The conference call-in number is 1–800–619–2521; passcode: 9271697.

• The webinar link is *https:// hrsa.connectsolutions.com/cogme.*

FOR FURTHER INFORMATION CONTACT: Kennita R. Carter, MD, Designated Federal Official, Division of Medicine and Dentistry, Bureau of Health Workforce, HRSA, Address: 5600 Fishers Lane, 15N–116, Rockville, Maryland 20857; (2) call 301–945–3505; or (3) send an email to *KCarter*@ *hrsa.gov.*

SUPPLEMENTARY INFORMATION:

Background: COGME provides advice and recommendations to the Secretary of HHS and to Congress on a range of issues, including: The nature and financing of medical education training; the development of performance measures and longitudinal evaluation methods of medical education programs; foreign medical school graduates; and the supply and distribution of the physician workforce in the United States, including any projected shortages or excesses. COGME submits reports to the Secretary of HHS; the Senate Committee on Health, Education, Labor, and Pensions; and the House of Representatives Committee on Energy and Commerce.

Agenda: During the meeting, the COGME members will discuss the strategic directions of the Council and issues related to physician workforce development and graduate medical education, leading to selection a topic for its 24th Report to Congress. An agenda will be available on the COGME website https://www.hrsa.gov/ advisorycommittees/bhpradvisory/ COGME/ prior to the meeting. Please note that agenda items are subject to change as priorities dictate.

Public Participation: Members of the public will have the opportunity to provide comments. Public participants may submit written statements in advance of the scheduled meeting. Oral comments will be honored in the order they are requested and may be limited as time allows. Requests to provide written statements or make oral comments to the COGME should be sent to Dr. Kennita R. Carter.

Since this meeting is held in a Federal government building, attendees must go through a security check to enter the building. Non-U.S. Citizen attendees must notify HRSA of their planned attendance at least 10 workdays prior to the meeting in order to facilitate their entry into the building. All attendees are required to present government-issued identification prior to entry. Individuals who plan to participate and require special assistance, such as sign language interpretation or other reasonable accommodations, should notify Dr. Kennita Carter, using the address and phone number above at least 10 business days prior to the meeting.

Amy P. McNulty,

Acting Director, Division of the Executive Secretariat.

[FR Doc. 2018–12512 Filed 6–8–18; 8:45 am] BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Request for Information (RFI): Input on Report From Council of Councils on Assessing the Safety of Relocating At-Risk Chimpanzees

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institutes of Health (NIH) is informing the research community and other interested parties that it received from the NIH Council of Councils the report of its Working Group on Assessing the Safety of Relocating At-Risk Chimpanzees, and the agency will consider recommendations contained in the report (see https://dpcpsi.nih.gov/sites/